Climb Bio (CLYM) vs CorMedix (CRMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Climb Bio (CLYM) has outperformed CorMedix (CRMD) over the past year, gaining 503.3% versus a loss of 35.0%. Over five years, CRMD leads with a +47.1% price change compared with -32.7% for CLYM. Climb Bio is the larger company by market cap ($623.8 million vs $570.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLYM | CRMD |
|---|---|---|
| Share price | $10.86 | $7.32 |
| Market cap | $623.76M | $570.55M |
| 1-day change | +1.40% | +0.55% |
| YTD return | +171.50% | -37.06% |
| 1-year return | +503.33% | -35.05% |
| 5-year return | -32.71% | +47.07% |
| P/E ratio (TTM) | — | 3.57 |
| Forward P/E | — | 20.91 |
| EPS (TTM) | $-0.82 | $2.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.33 | $13.02 |
| 52-week low | $1.64 | $6.13 |
| Distance from 52-week high | -40.75% | -43.78% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +153.87% | +109.43% |
| Average volume | 1.37M | 1.06M |
| Shares outstanding | 57.44M | 77.94M |
| Employees | 28 | 191 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed CRMD by 538.4 percentage points over the past year.
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Health Care · Biotechnology: Pharmaceutical Preparations · 191 employees
CLYM vs CRMD FAQ
Which is bigger, Climb Bio or CorMedix?
Climb Bio (CLYM) is larger, with a market capitalization of $623.76M compared with $570.55M for CorMedix (CRMD).
Which stock has performed better over the past year, CLYM or CRMD?
CLYM returned +503.33% over the past 12 months, compared with -35.05% for CRMD (price return, excluding dividends). Past performance does not predict future results.
Are Climb Bio and CorMedix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.